nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-F1ED5C5E·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.3 Neurology·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

Aberrant tau accumulation caused by MAPT mutations induces early pathological changes in axonal transport that are rescued by p38α inhibition.

Moretto et al.Moretto, Masato, Panzi et al.·2026·Nature neuroscience·10.1038/s41593-026-02266-4 ↗

Primary claim

deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death.

Supported · mouse-level evidence supports an early model-specific deficit, but very small female cohorts limit precision and generalisability
In brief

High-resolution in vivo imaging identifies early, pharmacologically reversible transport deficits in tauopathy, but pseudoreplicated culture analyses weaken the proposed tau-envelope mechanism.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Impairments in axonal transport have been implicated in the pathogenesis of tauopathies, including frontotemporal dementia and Alzheimer's disease, yet the underlying mechanisms and reversibility of these deficits are largely unknown. In particular, the impacts of tau mutations, phosphorylation and aggregation on axonal transport in vivo remain controversial. By using two-photon imaging of axonal transport of BDNF granules in the mouse cortex, we reveal that deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death. Mechanistically, these impairments are caused by the enlargement of tau envelopes on microtubules, which act as functional barriers for transport. Crucially, these deficits are reversed by inhibiting MAPK p38α. Together, our work demonstrates that tau pathology causes reversible deficits in axonal transport in vivo, posing the basis for pharmacological interventions to restore the physiological flux of axonal organelles and cargoes in tauopathies.

Key Claims

Primary finding · Supported

deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

mouse-level evidence supports an early model-specific deficit, but very small female cohorts limit precision and generalisability

Abstract; Results, Fig. 2
Quote verified
Secondary · Supported

these deficits are reversed by inhibiting MAPK p38α.

paired inhibitor experiments improve selected transport measures, though rescue is partial and treatment order is fixed

Abstract; Results, Figs. 2–4
Quote verified
Secondary · Tentative

tau envelopes function as obstacles for axonal transport

colocalisation, pause association, and correlative microscopy do not independently manipulate envelope size or establish causation

Results, Clusters of mutant tau on microtubules hinder axonal transport; Fig. 7
Quote verified
Secondary · Tentative

the activity of SB-239063 on axonal transport is largely dependent on the reduction of P301L tau phosphorylation levels.

phosphomutants are informative, but the inhibitor comparison being explained is non-significant and nested observations are not modeled

Results, Fig. 6
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Single-organelle cortical transport imaging

The two-photon assay follows BDNF-containing granules in cortico-cortical projections at substantially higher spatiotemporal resolution than the prior in vivo work described by the paper.

↳ Results, Fig. 1

#methodological rigour

Convergent genetic and pharmacological controls

Doxycycline suppression, the rTg21221 WT-tau line, phosphomutant constructs, and two p38 inhibitors test complementary parts of the proposed pathway.

↳ Figs. 2–6; Extended Data Fig. 1g–j

#positioning

Competing interpretations are discussed

The Discussion addresses contradictory transport studies, divergent taxol findings, incomplete rescue, and the possibility that the observed structures are small pathological aggregates rather than canonical envelopes.

↳ Discussion, both subsections

Limitations

#methodological rigour

Mechanistic analyses use clustered observations

Figs. 5–7 conduct inference on neurons or axons nested within three to five neuronal preparations; plotting preparation means does not account for that dependence.

↳ Figs. 5c,d, 6b,c and 7c–e,i

#reporting

Mechanistic wording exceeds reported evidence

The envelope-obstacle claim is largely correlational, while phosphorylation dependence and envelope-size restoration are stated despite non-significant direct comparisons in Figs. 6 and 7.

↳ Abstract; Figs. 6b,c and 7h,i; Discussion

#methodological rigour

Small and restricted in vivo cohorts

Central imaging comparisons use three to four mice per group and predominantly or exclusively female cohorts, limiting precision and generalisability despite paired designs.

↳ Figs. 2d, 3d and 4c,d legends

Does this match your read? Add your assessment ↓

Nabu Commentary

The strongest contribution is the in vivo observation that cortical BDNF-granule transport is impaired early in rTg4510 mice and improves on selected measures after p38 inhibition. Animal-level aggregation, paired imaging, genetic controls, and a second inhibitor support that direction of effect. The quality score is constrained by neuron- and axon-level inference across a small number of culture preparations, which weakens the phosphorylation and envelope mechanism. The abstract and Discussion also present the envelope mechanism and rescue more definitively than the correlational and partly non-significant evidence warrants.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.2±0.1

Contribution
3.9

The study meaningfully extends prior work by measuring BDNF-granule transport at single-organelle resolution in association-cortex projections and connecting early deficits to p38 inhibition. Its advance is strongest for the in vivo transport observation, while the detailed envelope mechanism remains less secure.

Results, Figs. 1–4; Discussion, In vivo axonal transport defects are caused by FTD-linked tau mutations

deficits in axonal transport arise in vivo at early stages of tau pathology

Methodological Rigour
2.5

Animal-level aggregation, paired imaging, genetic controls, two inhibitors, and blinded analysis support the in vivo arm. Central culture-mechanism tests nevertheless use neurons or axons as inferential observations despite clustering within three to five preparations, so the serious pseudoreplication ceiling binds.

Figs. 5c,d, 6b,c and 7c–e,i; Methods, Statistical analyses

Lighter ‘X’ symbols represent the averages per preparation.

Reporting
3.4

The progression from assay validation to in vivo rescue and cellular mechanism is easy to follow. Causal envelope language and statements of restoration or phosphorylation dependence are stronger than the correlational or non-significant comparisons support.

Abstract; Results, Figs. 6–7; Discussion, P301S/P301L mutant tau envelopes affect axonal transport

these impairments are caused by the enlargement of tau envelopes

Positioning
3.8

The paper engages conflicting in vivo transport findings, prior p38 studies, tau-envelope literature, and the taxol discrepancy. It acknowledges incomplete rescue and structural uncertainty but gives less attention to female-only central imaging, small animal samples, and model-specific limits on extrapolation to AD.

Discussion, P301S/P301L mutant tau envelopes affect axonal transport; Discussion, In vivo axonal transport defects are caused by FTD-linked tau mutations

we cannot exclude that they may correspond to small pathological aggregates

Lower confidence on Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

Track selection is described differently in the legends and Methods, one comparison has two differently reported P values, and an in vivo efficacy statement cites cultured-neuron experiments.

Ethics approval: declared · Preregistration: not stated · Data availability: declared

Reference IntegrityClean

83 references in manuscript 81 of 81 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is demonstrated in a tauopathy mouse model and cultured neurons under controlled laboratory conditions, with no human or clinical evidence presented.

From the paper
“posing the basis for pharmacological interventions to restore the physiological flux of axonal organelles and cargoes in tauopathies”

The paper names a real-world use of its findings, pharmacological intervention to restore axonal transport in tauopathies, but does not specify who would act on them.

Pathway

Drug developers and neurologists could advance p38α inhibitors such as neflamapimod as early-stage treatments for tauopathies that restore axonal transport.

Barrier

The findings rest on mutant-tau mouse models and acute imaging endpoints, so human trials must still show that p38α inhibition restores transport and slows clinical progression.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →